anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The participants in the current study were parents of children with CP aged 4-18 years. They were recruited at the Hacettepe University Physical Therapy and Rehabilitation Faculty Cerebral Palsy and Pediatric Rehabilitation Unit and Special Education and Rehabilitation Centers. The inclusion criteria were having a child with CP aged 2-18 years without severe cognitive problems, being a primary caregiver.
ABSTRACT         The specification describes and claims a paste-like preparation comprising (A) a paste-like base comprising a polyorganosiloxane and a water-soluble polymeric material which are preferably present in a ratio by weight from 3:6 to 6:3 and (B) an active ingredient.  The polyorganosiloxane is substantially linear and comprises predominantly R2SiO units and chain terminating units R'R2Si01/2 where each R represents a lower alkyl group, a halogenated alkyl group 9 an alkenyl group or an aryl group and each R' represents a group R or a hydroxyl group, and the polyorganosiloxane is a liquid or a gum at 25°C.  The water-soluble polymeric material may provide from 10 to 90%  by weight of the base and may be chosen from water-soluble polymers and copolymers of acrylic acid, methacrylic acid, acrylamide, cellulose derivatives and salts thereof, carboxymethylchitin, polyvinylpyrollidone, polyvinyl alcohol, starch derivatives, polyethylene oxide, gelatin, collagen and natural gums. The water-soluble polymeric material may be a particulate solid, the particles of which have a mean diameter of 2 to 100 micrometers.  The preparation may comprise up to 70% by weight of a paste adjusting component chosen from fatty materials.  The active ingredient may comprise for example a perfume, antiseptic or fertilizer or a drug, or quasi-drug, for example, a germicidal, antibiotic, anaesthetic, chemotherapeutic, vasodilator, expectorant, antianginal, hemostatic, gastrointestinal, antidiabetic, hormone or contraceptive agent.  The preparation is capable of adhering to wet surfaces such as mucosa and of releasing the active ingredient whilst adhered to the surface.
Presently there are no effective medical therapies to enhance blood flow in the legs of patients with peripheral vascular disease. For patients with limb threatening ischemia the only option for relief of rest pain or gangrene is amputation.

There is evidence in animal and clinical studies that adult stem cells in the bone marrow, called endothelial progenitor cells, participate in the development of new blood vessels, a process called angiogenesis. In this investigation, patients with limb threatening ischemia will have their bone marrow harvested and the stem cells will then be removed and injected directly into the muscle of the diseased leg. The procedure will require about 4 hours and the subjects will be admitted to the Indiana University Medical Center overnight. The follow-up period is 12 weeks and the analysis will consist of examinations at 1, 2, 4, 6, 8, and 12 weeks. Adverse and serious adverse events will be recorded during this time period. Diagnostic studies will be obtained to measure blood flow in the treated leg during the follow up period and include transcutaneous (skin) oxygen measurements, pressure recordings in the leg, arteriography, magnetic resonance imaging, and wound healing.
Physician-Led Professional Coaching is a one-on-one intervention between a physician coach and an individual physician that is systematic, collaborative, future-focused, goal-oriented and is meant to help coaches attain valued professional or personal development. The trial will be conducted with 25 participants in an intervention cohort and 25 participants in a control. The intervention cohort will receive 6 individual coaching sessions over 6 months. Coaching sessions will use the CHEER acronym for conducting the coaching sessions: Celebrate, Hear, Executive coaching, Engage, and Recharge. The control group will be eligible for coaching sessions after the completing of the interventional arm. Physicians randomized to the control arm will be offered the same individualized coaching sessions as those that were in the intervention group. Te Maslach Burnout Inventory survey will be used to measure burnout and will be collected at baseline, 3 months, 6 months, and 9 months. The physician coach will be blinded to all survey data as it is being collected.
SCOPE: Active ingredients in functional foods exhibit broad-spectrum antiviral activity. The objective of this study is to investigate the protective effect of quercetin derived from bee propolis, a natural product with antiviral activity and modulating effects on the gut microbiota, against vesicular stomatitis virus (VSV) infection.
METHODS AND RESULTS: Through a cellular-based study, this study demonstrates that quercetin can modulate the activity of interferon-regulating factor 3 (IRF3). In vivo, it shows that quercetin protects mice from VSV infection by enhancing interferon production and inhibiting the production of proinflammatory cytokines. The study conducts 16S rRNA-based gut microbiota and nontargets metabolomics analyses to elucidate the mechanisms underlying quercetin-mediated bidirectional communication between the gut microbiome and host metabolome during viral infection. Quercetin not only ameliorates VSV-induced dysbiosis of the intestinal flora but also alters serum metabolites related to lipid metabolism. Cross-correlations between the gut bacteriome and the serum metabolome indicate that quercetin can modulate phosphatidylcholine (16:0/0:0) and 5-acetylamino-6-formylamino-3-methyluracil to prevent VSV infection.
CONCLUSION: This study systematically elucidates the anti-VSV mechanism of quercetin through gut bacteriome and host metabolome assays, offering new insights into VSV treatment and revealing the mechanisms behind a novel disease management strategy using dietary flavonoid supplements.
An aptamer, capable of inhibiting DNA methyltransferase 1 (DNMT1) for use in therapy of diseases characterised by aberrant DNA methylation, e.g. cancer. Method for identifying inhibitors of DNA methyltransferase. An aptamer, capable of inhibiting DNA methyltransferase 1 (DNMT1) for use in therapy of diseases characterised by aberrant DNA methylation, e.g. cancer. SELEX method for identifying aptamers of DNA methyltransferase optionally using 2-fluoro-pyrimindine nucleotide derivatives.
Patients receive decitabine IV over 60 minutes on days -4 to 0 and undergo infusion of allogeneic NK cells on day 0. Beginning 1 hour after infusion allogeneic NK cells, patients also receive aldesleukin SC every other day for 6 doses.
The invention belongs toThe technical fields of pharmaceutical chemistry and pharmacology, and discloses 2,3, 6-trideoxy glycosyl mountain lotus leaf essence and a preparation method thereof. The 2,3, 6-trideoxy-mountain nuciferine compound has a structure shown in a formula (I): intermediate 1 is obtained from the reaction of mountain lotus leaf extract with 3-bromopropanol or 6-bromohexanol. Intermediate 1 undergoes allylic glycosylation with the corresponding tert-butylcarbonate-based pyrone to afford intermediate 2. The intermediate 2 and sodium borohydride undergo a Luche reduction reaction to obtain an intermediate 3. And (3) performing palladium-carbon hydrogen reduction on the double bond of the intermediate 3 in methanol to obtain the 2,3, 6-trideoxy glycosyl shan nuciferine 4. The 2,3, 6-trideoxy mountain lotus leaf compound obtained by the invention has stronger anti-tumor activity and can be used for preparing anti-tumor drugs.
A motion evaluation system, a method thereof and a computer-readable recording medium are provided. The motion evaluation system includes at least one sensor and a processor. The sensor generates a sensing data for a motion posture. The processor obtains the motion posture of the sensor, determines a continued time when the motion posture conforms to a correct posture, and sends a notification message according to the continued time. The correct posture is related to a degree between a portion under test and a reference object. Accordingly, the rehabilitation can be performed anytime and anywhere, and it is easier for tracking the rehabilitation situation.
In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with the administration of ATACAND HCT. 

Creatinine, Blood Urea Nitrogen— Minor increases in blood urea nitrogen (BUN) and serum creatinine were observed infrequently. One patient was discontinued from ATACAND HCT due to increased BUN. No patient was discontinued due to an increase in serum creatinine.

Hemoglobin and Hematocrit—Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.2 g/dL and 0.4 volume percent, respectively) were observed in patients treated with ATACAND HCT, but were rarely of clinical importance. 

Potassium— A small decrease (mean decrease of 0.1 mEq/L) was observed in patients treated with ATACAND HCT. In placebo-controlled trials, hypokalemia was reported in 0.4% of patients treated with ATACAND HCT as compared to 1.0% of patients treated with hydrochlorothiazide or 0.2% of patients treated with placebo. 

Liver Function Tests—Occasional elevations of liver enzymes and/or serum bilirubin have occurred.
Myocardial fibrosis, a common complication of myocardial infarction (MI), is characterized by excessive collagen deposition and can result in impaired cardiac function. The specific role of CD137 in the development of post-MI myocardial fibrosis remains unclear. Thus, this study aimed to elucidate the effects of CD137 signaling using CD137 knockout mice and in vitro experiments. CD137 expression levels progressively increased in the heart after MI, particularly in myofibroblast, which play a key role in fibrosis. Remarkably, CD137 knockout mice exhibited improved cardiac function and reduced fibrosis compared with wild-type mice at day 28 post-MI. The use of Masson's trichrome and picrosirius red staining demonstrated a reduction in the infarct area and collagen volume fraction in CD137 knockout mice. Furthermore, the expression of alpha-smooth muscle actin and collagen I, key markers of fibrosis, was decreased in heart tissues lacking CD137. In vitro experiments supported these findings because CD137 depletion attenuated cardiac fibroblast differentiation, and migration, and collagen I synthesis. In addition, the administration of CD137L recombinant protein further promoted alpha-smooth muscle actin expression and collagen I synthesis, suggesting a profibrotic effect. Notably, the application of an inhibitor targeting the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway attenuated the profibrotic effects of CD137L. To conclude, this study provides evidence that CD137 plays a significant role in promoting myocardial fibrosis after MI. Inhibition of CD137 signaling pathways may hold therapeutic potential for mitigating pathological cardiac remodeling and improving post-MI cardiac function.
The invention discloses frog meat protein source active peptide and application thereof in preparation of an immunomodulator, and belongs to the technical field of active peptides. The invention identifies two novel immunoregulatory peptides GIHETTYNS and IVRDIKEK from the hydrolysate of the rana spinosa meat, can obviously improve the proliferation activity of macrophage RAW264.7, accelerate the progress of cell cycle, promote the production of NO and cytokines and improve the level of active oxygen. The inflammatory reaction experimental result shows that the active peptide can relieve inflammatory reaction. Molecular docking results indicate that the active peptide binds to the critical region of TLR4/MD-2 through hydrogen bonding, hydrophobic interactions. In addition, bioinformatic analysis shows that the active peptide has good safety and stability. In conclusion, the active peptide is expected to be a new raw material of natural immunomodulators and anti-inflammatory agents, and promotes the high-value utilization of the rana spinosa.
Participants in the Passive Music Therapy arm will receive preoperative music therapy designed to reduce perioperative anxiety. The intervention will involve listening to calming music via headphones for a 20 minutes before entering the operating room.
All subjects will receive a single dose of metformin 1000 mg on Days 1 and 8 in a fasting state. Subjects will also receive a single i.v. dose of 60 mg copanlisib on Day 8 as part of the combination with metformin.
One of the main goals of orthodontic treatment is the reduction of treatment time through faster tooth movement, acceleration of canine retraction and space closure would reduce overall treatment time. Tooth movement is essentially a biological response to a physical stimulus, speeding up this response should avoid the occurrence of common iatrogenic effects such as white spot lesions, caries, root resorption and periodontal problems 1. Therefore, attempts to accelerate tooth movement and reduce treatment duration are of great significance to both orthodontists and patients. Thus, various invasive and non-invasive modalities have been attempted to reduce the duration of orthodontic treatment by accelerating tooth movement such as: surgical, vibration, pharmacological agents, low-level laser therapy or other procedures 2,3,4,5. However, none of these procedures have yet become a gold standard method. Platelet-based preparations from the patient's blood provide a safe alternative to commercially available bioactive materials. Platelet-rich fibrin (PRF) is the second generation, holds the advantages of easier preparations and longer effects 6-11. The injectable platelet-rich fibrin (i-PRF) was developed as an advanced product of PRF by altering the centrifugation protocol by lowering the centrifugation speed and force to 700 rotations per minute within 3 minutes. has many advantages over the conventional form such as higher rates of leukocyte, regenerative cells and growth factors. The potential benefits of PRF have been widely investigated in regenerative dentistry and oral surgery such as tooth movement, implantology, oral pathology and periodontal therapy 12,13,14. Wang et al. reported that i-PRF affected osteoblastic behavior remarkably by influencing its migration, proliferation, and differentiation. This promotes cellular activity and accelerates bone turnover and healing 11.

The purpose of this study was to investigate the efficiency of i-PRF in accelerating tooth movement.
Subjects in the simvastatin arm will receive simvastatin 20 mg daily for 6 weeks before having their lipids checked. If their LDL-c decreases by less than 35% from screening, then the dose of simvastatin is increased to 40 mg daily for the following 6 weeks.
NAC transcription factors (TFs) are pivotal in plant immunity against diverse pathogens. Here, we report the functional and regulatory network of MNAC3, a novel NAC TF, in rice immunity. MNAC3, a transcriptional activator, negatively modulates rice immunity against blast and bacterial leaf blight diseases and pathogen-associated molecular pattern (PAMP)-triggered immune responses. MNAC3 binds to a CACG cis-element and activates the transcription of immune-negative target genes OsINO80, OsJAZ10, and OsJAZ11. The negative function of MNAC3 in rice immunity depends on its transcription of downstream genes such as OsINO80 and OsJAZ10. MNAC3 interacts with immunity-related OsPP2C41 (a protein phosphatase), ONAC066 (a NAC TF), and OsDjA6 (a DnaJ chaperone). ONAC066 and OsPP2C41 attenuate MNAC3 transcriptional activity, while OsDjA6 promotes it. Phosphorylation of MNAC3 at S163 is critical for its negative functions in rice immunity. OsPP2C41, which plays positive roles in rice blast resistance and chitin-triggered immune responses, dephosphorylates MNAC3, suppressing its transcriptional activity on the target genes OsINO80, OsJAZ10, and OsJAZ11 and promoting the translocation of MNAC3 from nucleus to cytoplasm. These results establish a MNAC3-centered regulatory network in which OsPP2C41 dephosphorylates MNAC3, attenuating its transcriptional activity on downstream immune-negative target genes in rice. Together, these findings deepen our understanding of molecular mechanisms in rice immunity and offer a novel strategy for genetic improvement of rice disease resistance.
Patients in Group A will have to consume two cup (250ml for each cup) of hot green tea, five days per week for 6 months. A tea bag is brewed in 250ml hot water for 3 minutes.
Severity of COVID-19 will be determined based on patient classification within the PACT (Johns Hopkins Post-acute COVID-19 Team) clinic. Specifically, patients followed in the PACT-ICU clinic required ICU stays of ≥48 hours and high-flow nasal cannula/non-invasive ventilation or mechanical ventilation. Those followed in the PACT-Base clinic have less severe disease that does not necessitate ≥48 hours in the ICU but does qualify for PACT clinic referral based on either (1) ongoing pulmonary and/or rehabilitation needs at the time of hospital discharge, or (2) persistent pulmonary or functional deficits at 4-6 weeks post infection without hospitalization.
PURPOSE:To obtain a 2-oxycephalosporin deriv. in high yields with extremely simple operations by electrolytically oxidizing a cephalosporin deriv. CONSTITUTION:The cerphalosporin deriv. expressed by the formulaI(e.g.; 7- phenoxyacetamide acetoxycephalosporic methyl ester) is electrolytically oxidized in the presence of generally a proton donative solvent (e.g.; acetic acid), more preferably a supporting electrolyte such as potassium acetate. Here, it is preferable to use the proton donative solvent 5-100 times the content of the cephalosporin deriv. A platinum or carbon electrode is preferable for the electrode, and the electrolysis may be effected under conditions of either constant potential or constant voltage. As a result of the electrolytic oxidation, the 2-oxycephalosporin deriv. expressed by the formula II[(e.g.;6R, 7S)-2-acetoxy-7-phenoxyacetamide acetoxycephalosporic methyl ester]is obtained. The compd. is important as a synthetic intermediate for cephalosporin type antibiotics, etc.
FIELD: pharmaceutical industry.SUBSTANCE: group of inventions relates to treating arthritis in a cat and dogs, increasing average life span, a method of preserving mobility or preventing mobility impairment, or as a method of slowing down aging. Use of composition containing 50 mcmol of green tea extract, 0.5 mg/ml hydrolysed collagen and 200 mcg/ml chondroitin, for preventing or treating arthritis in a cat or dog. Use of composition containing 50 mcmol of green tea extract, 0.5 mg/ml hydrolysed collagen and 200 mcg/ml chondroitin, to increase average life expectancy in a cat or dog. Use of composition containing 50 mcmol of green tea extract, 0.5 mg/ml hydrolysed collagen and 200 mcg/ml chondroitin to slow down aging in cat or dog. A method for treating arthritis in a cat or dog, comprising administering to an animal composition comprising 50 mcmol of green tea extract, 0.5 mg/ml hydrolysed collagen and 200 mcg/ml chondroitin. A method for increasing average life expectancy in a cat or dog, comprising administering to an animal composition comprising 50 mcmol of green tea extract, 0.5 mg/ml hydrolysed collagen and 200 mcg/ml chondroitin. A method for slowing aging of a cat or dog, involving administering to said animal composition containing 50 mcmol of green tea extract, 0.5 mg/ml hydrolysed collagen and 200 mcg/ml chondroitin.EFFECT: above described inventions are effective for treating arthritis in a cat and a dog, increasing average life span, preserving mobility or preventing mobility impairment, to slow down aging.9 cl, 4 dwg, 4 tbl, 2 ex
The high permeability medicine composition for preparing pre-nacrosis medicine consists of one or several crystals selected from sodium chloride, sodium bicarbonate, potassium chloride, magnesium sulfate, calcium chloride, calcium gluconate, etc. in 1.5-6.9 wt%; one or several colloids selected from hydroxyethyl starch, dextran, carboxymethyl starch, etc. in 3-18 wt%; and conventional injection. It has sodium chloride concentration not lower than 1.5 wt%. It is injected before nacrosis in the dosage of 100-500 ml and can reduce cardiac vascular disorder. It has the advantages of being safe and convenient, high in curative effect, long acting time and wide use.
Up to 50 subjects (up to 25 with healthy skin or 25 with atopic dermatitis) meeting the inclusion criteria will be enrolled in this study. A physical exam will be performed to ensure the subjects have healthy skin versus atopic dermatitis. For atopic dermatitis subjects, AD severity will be graded by the EASI score. Site randomization will be performed to determine which cleansers will be used for each of the 8 test sites (one site will be randomized to act as a control and not receive any cleanser). Baseline skin barrier function (TEWL, pH and hydration) will be measured. Then 1ml of each cleansers will be applied to the corresponding test sites, 2ml of tap water will be added, and lathered in a circular motion for 15 seconds. The sites will then be rinsed off with tap water for 15 seconds. Arms will be padded dry. Barrier functions will be measured again immediately after padding dry, and at 30, 60 and 90 minutes after.
The choroid, a vascularized tissue situated between the retina and the sclera, plays a crucial role in maintaining ocular homeostasis. Despite its significance, research on choroidal abnormalities and the establishment of effective in vitro models have been limited. In this study, we developed an in vitro choroid model through the co-culture of human induced pluripotent stem cells (hiPSC)-derived endothelial cells (ECs) and mouse choroidal fibroblasts (msCFs) with hiPSC-derived retinal pigment epithelial (RPE) cells via a permeable membrane. This model, inclusive of ECs, CFs, and RPE cells, exhibited similarities with in vivo choroidal vessels, as confirmed through immunohistochemistry of extracellular matrix markers and vascular-related markers, as well as choroid angiogenesis sprouting assay analysis. The effectiveness of our in vitro model was demonstrated in assessing vascular changes induced by drugs targeting vasoregulation. Our model offers a valuable tool for gaining insights into the pathological mechanisms underlying choroid development and the progression of choroidal vascular diseases.
While animal prion diseases are a threat to human health, their zoonotic potential is generally inefficient because of interspecies prion transmission barriers. New animal models are required to provide an understanding of these prion transmission barriers and to assess the zoonotic potential of animal prion diseases. To address this goal, we generated Drosophila transgenic for human or nonhuman primate prion protein (PrP) and determined their susceptibility to known pathogenic prion diseases, namely varient Creutzfeldt-Jakob disease (vCJD) and classical bovine spongiform encephalopathy (BSE), and that with unknown pathogenic potential, namely chronic wasting disease (CWD). Adult Drosophila transgenic for M129 or V129 human PrP or nonhuman primate PrP developed a neurotoxic phenotype and showed an accelerated loss of survival after exposure to vCJD, classical BSE, or CWD prions at the larval stage. vCJD prion strain identity was retained after passage in both M129 and V129 human PrP Drosophila. All of the primate PrP fly lines accumulated prion seeding activity and concomitantly developed a neurotoxic phenotype, generally including accelerated loss of survival, after exposure to CWD prions derived from different cervid species, including North American white-tailed deer and muntjac, and European reindeer and moose. These novel studies show that primate PrP transgenic Drosophila lack known prion transmission barriers since, in mammalian hosts, V129 human PrP is associated with severe resistance to classical BSE prions, while both human and cynomolgus macaque PrP are associated with resistance to CWD prions. Significantly, our data suggest that interspecies differences in the amino acid sequence of PrP may not be a principal determinant of the prion transmission barrier.